Medical marijuana programs in Canada, Germany, and Thailand show industry pressure outpacing evidence
Drawing from Canada, Germany, and Thailand, this review argues that cannabis industry pressure and self-medication trends are driving medical marijuana expansion faster than the evidence for most claimed indications.
Quick Facts
What This Study Found
Two pressures drive medical marijuana expansion: patients self-medicating for conditions without evidence of cannabis effectiveness, and cannabis industry lobbying for lenient regulations. Canada (early adopter), Germany (late adopter), and Thailand (middle-income) all illustrate this pattern. Lenient regulations that only require a prescription without specifying indications are likely to increase demand.
Key Numbers
Three countries analyzed: Canada (early adopter), Germany (late adopter), Thailand (middle-income). Evidence lacking for many self-medication indications.
How They Did This
Policy analysis comparing medical marijuana programs in three countries: Canada, Germany, and Thailand.
Why This Research Matters
Medical marijuana programs are often seen as harm reduction, but if regulations are too lenient, they can become de facto recreational legalization without appropriate safety oversight.
The Bigger Picture
The global shift toward medical cannabis legalization is driven by a mix of genuine patient needs, cultural trends, and industry interests. Policymakers need frameworks that balance access with evidence requirements.
What This Study Doesn't Tell Us
Policy analysis with limited quantitative data. Focuses on three countries that may not represent all regulatory approaches. Industry influence is asserted but not quantified.
Questions This Raises
- ?Should medical marijuana programs require evidence-based indications?
- ?How do you balance patient access with evidence requirements?
- ?Does industry pressure ultimately help or harm patients?
Trust & Context
- Key Stat:
- No evidence of effectiveness for many self-medication indications
- Evidence Grade:
- Moderate: thoughtful policy analysis drawing from multiple countries, but limited to qualitative assessment.
- Study Age:
- Published in 2019.
- Original Title:
- Medical marijuana. What can we learn from the experiences in Canada, Germany and Thailand?
- Published In:
- The International journal on drug policy, 74, 47-51 (2019)
- Authors:
- Rehm, Jürgen(12), Elton-Marshall, Tara(3), Sornpaisarn, Bundit, Manthey, Jakob
- Database ID:
- RTHC-02254
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is medical marijuana just recreational in disguise?
In some jurisdictions with lenient regulations (requiring only a prescription without specific indications), the line can blur. The authors argue for clearer evidence requirements to maintain the distinction.
Does this mean medical marijuana doesn't work?
Not for all conditions. The review acknowledges that cannabis has proven benefits for some indications but argues that many conditions for which patients self-medicate lack evidence of effectiveness.
Read More on RethinkTHC
Cite This Study
https://rethinkthc.com/research/RTHC-02254APA
Rehm, Jürgen; Elton-Marshall, Tara; Sornpaisarn, Bundit; Manthey, Jakob. (2019). Medical marijuana. What can we learn from the experiences in Canada, Germany and Thailand?. The International journal on drug policy, 74, 47-51. https://doi.org/10.1016/j.drugpo.2019.09.001
MLA
Rehm, Jürgen, et al. "Medical marijuana. What can we learn from the experiences in Canada, Germany and Thailand?." The International journal on drug policy, 2019. https://doi.org/10.1016/j.drugpo.2019.09.001
RethinkTHC
RethinkTHC Research Database. "Medical marijuana. What can we learn from the experiences in..." RTHC-02254. Retrieved from https://rethinkthc.com/research/rehm-2019-medical-marijuana-what-can
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.